Rohit Loomba, MD, MHSc

Rohit Loomba, MD, MHSc

University of California, San Diego

H-index: 125

North America-United States

About Rohit Loomba, MD, MHSc

Rohit Loomba, MD, MHSc, With an exceptional h-index of 125 and a recent h-index of 112 (since 2020), a distinguished researcher at University of California, San Diego, specializes in the field of NAFLD, NASH, cirrhosis, liver disease, outcomes.

His recent articles reflect a diverse array of research interests and contributions to the field:

Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease

Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States

Factors that mediate change in creatinine and acute kidney injury after the Norwood operation: insights from high-fidelity haemodynamic monitoring data

Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD

Velacur ACE outperforms FibroScan CAP for diagnosis of MASLD

The Impact of Stigma on Quality of Life and Liver Disease Burden Among Patients with Nonalcoholic Fatty Liver Disease

Author Correction: Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort

Association between balloon atrial septostomy and prostaglandin E1 therapy until repair of transposition of the great arteries in neonates

Rohit Loomba, MD, MHSc Information

University

Position

___

Citations(all)

67155

Citations(since 2020)

54138

Cited By

64367

hIndex(all)

125

hIndex(since 2020)

112

i10Index(all)

494

i10Index(since 2020)

461

Email

University Profile Page

University of California, San Diego

Google Scholar

View Google Scholar Profile

Rohit Loomba, MD, MHSc Skills & Research Interests

NAFLD

NASH

cirrhosis

liver disease

outcomes

Top articles of Rohit Loomba, MD, MHSc

Title

Journal

Author(s)

Publication Date

Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease

Rohit Loomba

Vincent Wai‐Sun Wong

2024/1

Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States

Alimentary Pharmacology & Therapeutics

Samer Gawrieh

Eduardo Vilar‐Gomez

Tinsay A Woreta

Jordan E Lake

Laura A Wilson

...

2024/3

Factors that mediate change in creatinine and acute kidney injury after the Norwood operation: insights from high-fidelity haemodynamic monitoring data

Cardiology in the Young

Rohit S Loomba

Sheena Mansukhani

Joshua Wong

2024/4/12

Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD

Clinical Gastroenterology and Hepatology

Chaowapong Jarasvaraparn

Eduardo Vilar-Gomez

Katherine P Yates

Laura A Wilson

Brent Neuschwander-Tetri

...

2024/5/1

Velacur ACE outperforms FibroScan CAP for diagnosis of MASLD

Hepatology Communications

Rohit Loomba

Alnoor Ramji

Tarek Hassanein

Eric M Yoshida

Emily Pang

...

2024/4/1

The Impact of Stigma on Quality of Life and Liver Disease Burden Among Patients with Nonalcoholic Fatty Liver Disease

JHEP Reports

Zobair M Younossi

Saleh A AlQahtani

Jesús Funuyet-Salas

Manuel Romero-Gómez

Yusuf Yilmaz

...

2024/3/12

Author Correction: Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort

Nature Genetics

Youwen Qin

Aki S Havulinna

Yang Liu

Pekka Jousilahti

Scott C Ritchie

...

2024/2/29

Association between balloon atrial septostomy and prostaglandin E1 therapy until repair of transposition of the great arteries in neonates

Pediatric Investigation

Samantha Gilg

Sebastian Acosta

Rohit S Loomba

Claire Rizk

Gary E Stapleton

...

2024

Relationship of non-invasive measures with histological response in patients with nonalcoholic steatohepatitis and fibrosis: 52-week data from the Phase 3 MAESTRO-NASH trial

Zeitschrift für Gastroenterologie

Jörn M Schattenberg

Rohit Loomba

Rebecca A Taub

Dominic Labriola

Noureddin Mazen

...

2024/1

Development and validation of the nonalcoholic fatty liver disease familial risk score to detect advanced fibrosis: a prospective, multicenter study

Clinical Gastroenterology and Hepatology

Daniel Q Huang

Noora Ahlholm

Panu K Luukkonen

Kimmo Porthan

Maral Amangurbanova

...

2024/1/1

Exercise training improves serum biomarkers of liver fibroinflammation in patients with metabolic dysfunction‐associated steatohepatitis

Liver International

Sara J Harris

Nataliya Smith

Breianna Hummer

Ian R Schreibman

Alison J Faust

...

2024/2

Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study

Hepatology Communications

Arun J Sanyal

Rohit Loomba

Quentin M Anstee

Vlad Ratziu

Kris V Kowdley

...

2024/1/1

Rising global burden of cancer attributable to high BMI from 2010 to 2019

Metabolism

Darren Jun Hao Tan

Cheng Han Ng

Mark Muthiah

Jie Ning Yong

Douglas Chee

...

2024/3/1

A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States

Alimentary Pharmacology & Therapeutics

Nikita Mittal

Harris Siddiqi

Egbert Madamba

Lisa Richards

Ricki Bettencourt

...

2024/4/8

Metabolic dysfunction–associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on …

Georgia Sofia Karachaliou

Ayako Suzuki

2024/1/1

Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification

Min Kyu Kang

Jeong Song

Rohit Loomba

Soo Park

Won Tak

...

2024/3/5

Pulmonary Atresia with Intact Ventricular Septum: Midterm Outcomes from a Multicenter Cohort

Pediatric cardiology

Ilias Iliopoulos

Christopher W Mastropietro

Saul Flores

Eva Cheung

Venugopal Amula

...

2024/4

Disruption of gut barrier integrity and host–microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus

Gut Microbes

R Forlano

L Martinez-Gili

P Takis

J Miguens-Blanco

T Liu

...

2024/12/31

MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH

Gut

Rohit Loomba

Maral Amangurbanova

Ricki Bettencourt

Egbert Madamba

Harris Siddiqi

...

2024/2/28

NASH is the leading cause of hepatocellular carcinoma in liver transplant candidates

Clinical Gastroenterology and Hepatology

Jia Hong Koh

Cheng Han Ng

Benjamin Nah

Darren Jun Hao Tan

Rohit Loomba

...

2024/1/1

See List of Professors in Rohit Loomba, MD, MHSc University(University of California, San Diego)